TICKERNOMICS Sign up
Last Update: 2023-12-23 05:59:57
EQRx Inc. ( EQRX ) https://www.eqrx.com
2.34USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
EQRX
4.46%
SPY
30.72%
EQRX
0.00%
SPY
112.82%
EQRX
0.00%
SPY
201.04%
EQRX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1133.10
239.69
16.55
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-13.52
0.00
0.97
-27.97
0.00
-0.52
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-42.75
-25.65
0.00
Other Earnings and Cash Flow Stats:
EQRx Inc. ( EQRX ) Net Income TTM ($MM) is -90.85
EQRx Inc. ( EQRX ) Operating Income TTM ($MM) is -394.44
EQRx Inc. ( EQRX ) Owners' Earnings Annual ($MM) is 0.00
EQRx Inc. ( EQRX ) Current Price to Owners' Earnings ratio is 0.00
EQRx Inc. ( EQRX ) EBITDA TTM ($MM) is -459.60
EQRx Inc. ( EQRX ) EBITDA Margin is 0.00%
Capital Allocation:
EQRx Inc. ( EQRX ) has paid 0.00 dividends per share and bought back -8.663719 million shares in the past 12 months
EQRx Inc. ( EQRX ) has reduced its debt by 1.339 million USD in the last 12 months
Capital Structure:
EQRx Inc. ( EQRX ) Interest-bearing Debt ($MM) as of last quarter is 3
EQRx Inc. ( EQRX ) Annual Working Capital Investments ($MM) are -398
EQRx Inc. ( EQRX ) Book Value ($MM) as of last quarter is 1170
EQRx Inc. ( EQRX ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
EQRx Inc. ( EQRX ) has 315 million in cash on hand as of last quarter
EQRx Inc. ( EQRX ) has 65 million of liabilities due within 12 months, and long term debt 0 as of last quarter
EQRx Inc. ( EQRX ) has 484 common shares outstanding as of last quarter
EQRx Inc. ( EQRX ) has 0 million USD of preferred stock value
Academic Scores:
EQRx Inc. ( EQRX ) Altman Z-Score is 9.01 as of last quarter
EQRx Inc. ( EQRX ) Piotroski Score is 0.00 as of last quarter
Corporate Governance:
EQRx Inc. ( EQRX ) largest shareholder is TANG CAPITAL MANAGEMENT LLC owning 10086110 shares at 23.60 ($MM) value
(an insider) shares of EQRx Inc. ( EQRX ) for the amount of $ on
11.14% of EQRx Inc. ( EQRX ) is held by insiders, and 68.24% is held by institutions
EQRx Inc. ( EQRX ) went public on 2021-12-20
Other EQRx Inc. ( EQRX ) financial metrics:
FCF:-316.92
Unlevered Free Cash Flow:0.00
EPS:-0.68
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-28.23
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About EQRx Inc. ( EQRX ) :
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.